The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

Bank of America reaffirmed its Buy rating for Eli Lilly, setting a price target of $1,268. Analyst Jason Gerberry noted that the trial data strengthens the company's competitive stance against rival ...

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

Eli Lilly's late-stage trial revealed that patients who switched from the injectable medications Wegovy and Zepbound to orforglipron were able to maintain a substantial portion of their weight loss.

The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance ...

Eli Lilly and Co. announced Thursday, Dec. 18 that its experimental daily GLP-1 pill, orforglipron, successfully helped ...

On the policy front, the U.S. Senate passed the Biosecure Act, legislation designed to limit federal reliance on certain foreign biotechnology companies viewed as national security risks. The measure ...

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Congress is leaving town for the holidays — and another year has gone by, with bipartisan pharmacy benefit manager legislation still on the flight deck.

The pharmaceutical sector's most intense rivalry is escalating. Eli Lilly has unveiled pivotal Phase 3 trial results for its ...

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...